Spike S1, Recombinant, SARS-CoV-2, aa13-665, Fc Fusion, Avi-tag (SARS-CoV-2)

Katalog-Nummer 544475-100ug

Size : 100ug

Marke : US Biological

Contact local distributor :


Telefonnummer : +1 850 650 7790


544475 Spike S1, Recombinant, SARS-CoV-2, aa13-665, Fc Fusion, Avi-tag (SARS-CoV-2)

Clone Type
Polyclonal
Swiss Prot
P0DTC2
Grade
Purified
Accession #
QHD43416.1
Shipping Temp
Dry Ice
Storage Temp
-70°C

Recombinant protein corresponding to aa13-665 from Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), fused at the C-terminus of the Fc portion of human IgG1, and a C-terminal Avi-tag, expressed in a HEK293 cells.||Molecular Weight:|~102kD, runs at a higher MW by SDS-PAGE due to glycosylation.||Assay Conditions:|SARS-CoV-2 S1 and ACE2 binding assay was done using ACE2:SARS-CoV-2 Spike Inhibitor Screening Assay Kit. SARS-CoV-2 S1 protein and anti-human Fc-HRP were used instead of SARS-CoV-2 Spike protein (RBD) and anti-mouse Fc-HRP respectively. Non-specific His-tag protein was coated and used for a negative control.||Applications: |Suitable for use in the study of enzyme kinetics, screening inhibitors and selectivity profiling. Other applications have not been tested. ||Recommended Dilution:|Optimal dilutions to be determined by the researcher.||Storage and Stability:|Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Applications
Source: Recombinant, HEK293 cells|Purity: ≥90% (SDS-PAGE)|Concentration: ~0.5mg/ml|Form: Supplied as a liquid in PBS, pH 7.4, 20% glycerol.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Form
Supplied as a liquid in PBS, pH 7.4, 20% glycerol.
Purity
≥90% (SDS-PAGE)
References
1. Hoffman, M. et al., Cell. 2020 Apr; 181:1-10.|2. Walls, A. C. et al., Cell. 2020 Mar; 180(2):281-292.